Peer-influenced content. Sources you trust. No registration required. This is HCN.

Cancer Therapy AdvisorToripalimab Plus Chemo Dubbed New Standard First-Line Therapy for ES-SCLC

The median progression-free survival was 5.8 months with toripalimab plus chemotherapy and 5.6 months with chemotherapy alone.

In a significant development in the field of oncology, a recent study presented at the ESMO Congress 2023 has highlighted the efficacy of toripalimab in combination with chemotherapy as a first-line therapy for patients with newly diagnosed extensive-stage small cell lung cancer (ES-SCLC).

Key Points

  • The study, known as the phase 3 EXTENTORCH trial, included 442 patients with ES-SCLC who had received no prior systemic therapy.
  • Patients were randomly assigned to receive toripalimab plus chemotherapy or placebo plus chemotherapy.
  • The median progression-free survival (PFS) was 5.8 months with toripalimab and 5.6 months with placebo.
  • The 1-year PFS rate was 18.1% in the toripalimab arm and 4.9% in the placebo arm.
  • The median overall survival (OS) was 14.6 months with toripalimab and 13.3 months with placebo.
  • The 1-year OS rate was 63.1% in the toripalimab arm and 54.9% in the placebo arm.
  • A biomarker analysis showed that tumor mutational burden was not associated with PFS or OS.

Despite being less common than non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) is more aggressive and rapidly spreads throughout the body. Interestingly, SCLC accounts for about 15% of all lung cancer diagnoses in the United States each year. Due to its rapid growth, in 60% of SCLC cases, the cancer has already metastasized to other areas in the body by the time it is diagnosed.

More on Small Cell Lung Cancer

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form